Hope found in magic mushrooms and MDMA

hopefound

Psychedelic drugs could revolutionise current treatment options for mental health conditions as growing evidence demonstrates the profound effects of Psilocybin and MDMA. Over 100 studies in the US have examined the effectiveness of psilocybin (found in magic mushrooms) for depression and MDMA for treating post-traumatic stress disorder (PTSD). Both psychedelics, when used under a medically controlled environment have displayed remarkable outcomes for such conditions.

Psilocybin turns off parts of the brain that enable new brain pathways to evolve, permitting emotions to be “reworked and regenerated”, Dr. Stephen Bright for Psychedelic Research in Science and Medicine (PRISM).

“By allowing an individual to experience psychedelics in a therapeutic setting, they have the opportunity to change rigid their ways of thinking and provide new insight or realisations in their lives.”. Research has shown in some cases up to 67 percent of individuals treated it MDMA no longer met the criteria for PTSD anymore.

Unfortunately, the illicit nature of psychedelics means many people are relying on self-administering and sourcing underground psychotherapists. Clinical trials have a lengthy yet necessary way to go in Australia. Researchers are wanting to ensure safety, efficacy and proper integration into the Australian healthcare system for equitable access.

Read the full article here. https://www.theadvocate.com.au/story/6290144/hope-found-in-magic-mushrooms-and-mdma/

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search